• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    6/17/24 1:21:47 PM ET
    $AAN
    $AGRI
    $ALLG
    $AMCX
    Diversified Commercial Services
    Consumer Discretionary
    Metal Fabrications
    Industrials
    Get the next $AAN alert in real time by email

    Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint.

    Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

    AMMO shares dipped 19.1% to $2.0306 on Friday.

    Here are some other stocks moving in today’s mid-day session.

    Gainers

    • Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday.
    • Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy data from the complete Waldenstrom Macroglobulinemia cohort of its Phase 1/2 clinical trial of MB-106, showing an overall response rate of 90% with one patient remaining in complete remission at 31 months.
    • Allego N.V. (NASDAQ:ALLG) gained 126.4% to $1.6750 after the company and its majority shareholder, Meridiam, announced a transaction framework agreement under which Meridiam will launch a tender offer for all issued and outstanding Allego shares not owned by Meridiam, with the option to tender shares for $1.70 per share in cash.
    • Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) shares gained 92.6% to $6.74 after surging 24% on Friday. Scinai Immunotherapeutics, last week, received a non-binding Letter of Intent from the European Investment Bank for converting loan into equity.
    • TRxADE HEALTH, Inc. (NASDAQ:MEDS) rose 47% to $9.50.
    • The Aaron’s Company, Inc. (NYSE:AAN) gained 32.2% to $9.97 after the company announced that it entered into a definitive agreement to be acquired by IQVentures Holdings.
    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) jumped 27% to $0.1044 after the company announced a $1 million share repurchase program.
    • Xponential Fitness, Inc. (NYSE:XPOF) surged 21.3% to $13.68. Xponential Fitness announced the appointment of Mark King as Chief Executive Officer.
    • Silynxcom Ltd. (NASDAQ:SYNX) gained 21.8% to $3.14.
    • Venus Concept Inc. (NASDAQ:VERO) gained 13.6% to $1.0650 after the company announced that it has entered a new strategic resurfacing and skin tightening device supply arrangement with Skin Laundry Holdings.
    • Envirotech Vehicles, Inc. (NASDAQ:EVTV) rose 12.8% to $1.4899.
    • CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) gained 12.8% to $3.1459. CNS Pharmaceuticals recently announced pricing of registered direct offering and concurrent private placement.
    • ENDRA Life Sciences Inc. (NASDAQ:NDRA) gained 11.8% to $0.1159 after a 13G filing showed a 9.99% passive stake from S.H.N. Financial Investments Ltd.
    • Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) climbed 10.5% to $2.0099. HC Wainwright & Co. analyst Joseph Pantginis initiated coverage on Lexicon Pharmaceuticals with a Buy rating and announced a price target of $10.
    • XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) shares climbed 10.5% to $2.31 after falling around 5% on Friday. XTL recently entered into definitive agreement to acquire The Social Proxy.
    • Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) gained 10.2% to $28.58. Mirum’s Volixibat achieved interim analyses in VANTAGE PBC and VISTAS PSC studies.
    • Ouster, Inc. (NYSE:OUST) shares rose 8.5% to $11.21. Ouster Director Virginia Boulet bought a total of 10,000 shares at an average price of $10.30.
    • Primo Water Corporation (NASDAQ:PRMW) gained 7.8% to $24.08 after the company and BlueTriton agreed to merge.

    Losers

    • Aerovate Therapeutics, Inc. (NASDAQ:AVTE) shares dipped 90.8% to $2.26 after the company reported 24-week topline results from phase 2b portion of IMPAHCT evaluating AV-101 for pulmonary arterial hypertension.
    • Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) shares dipped 33% to $3.9950. Kaival Brands Innovations Group shares jumped 338% on Friday after the company announced a $5 million offering of 3,012,048 units at $1.66 per unit.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 29.4% to $0.36 in pre-market trading after jumping 12% on Friday.
    • Workhorse Group Inc. (NASDAQ:WKHS) declined 26% to $2.22. Workhorse announced a 1-for-20 reverse stock split of its common stock last week after shareholders approved the move at the company's annual meeting of stockholders in May.
    • AMC Networks Inc. (NASDAQ:AMCX) fell 25.7% to $11.67 after the company announced a private offering of $125 million of convertible senior notes.
    • iPower Inc. (NYSE:IPW) shares fell 24.4% to $2.49 after the company announced a $5 million registered direct offering.
    • Scorpius Holdings, Inc. (NASDAQ:SCPX) fell 21.3% to $0.0763 after the company received NYSE American notice of delisting and reported plans to appeal.
    • Atara Biotherapeutics, Inc. (NASDAQ:ATRA) declined 20.8% to $0.4044. Atara Biotherapeutics announced a 1-for-25 reverse stock split.
    • 22nd Century Group, Inc. (NASDAQ:XXII) dipped 20.7% to $0.6405.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) fell 20.6% to $1.19. SELLAS Life Sciences announced review of ongoing Phase 3 REGAL clinical trial of Galinpepimut-S in acute myeloid leukemia by IDMC.
    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) dipped 19.6% to $11.00.
    • Feutune Light Acquisition Corporation (NASDAQ:FLFV) shares fell 18.5% to $7.99.
    • MYT Netherlands Parent B.V. (NASDAQ:MYTE) declined 13.1% to $4.31.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) fell 12.8% to $4.9190.
    • BIMI Holdings Inc. (NASDAQ:BIMI) shares fell 12.6% to $1.92 after gaining 23% on Friday.
    • Cemtrex, Inc. (NASDAQ:CETX) fell 12.2% to $0.2451.
    • La Rosa Holdings Corp. (NASDAQ:LRHC) shares declined 11.1% to $1.04. La Rosa Holdings shares jumped around 76% on Friday after the company filed a request for the withdrawal of its registration statement on a Form S-1.
    • Evotec SE (NYSE:EVO) shares declined 10.5% to $4.07.
    • ZKH Group Limited (NYSE:ZKH) fell 10.2% to $3.5850. ZKH Group recently announced a $50 million share repurchase program.
    • Bitdeer Technologies Group (NASDAQ:BTDR) declined 9% to $9.05.
    • FuelCell Energy, Inc. (NASDAQ:FCEL) fell 6.8% to $0.7636.
    • Louisiana-Pacific Corporation (NYSE:LPX) declined 6.3% to $86.25 after Goldman Sachs downgraded the stock from Neutral to Sell and lowered its price target from $89 to $81.
    • Coeur Mining, Inc. (NYSE:CDE) fell 5.3% to $5.44.

    Now Read This: Wall Street’s Most Accurate Analysts Spotlight On 3 Materials Stocks Delivering High-Dividend Yields

    Get the next $AAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAN
    $AGRI
    $ALLG
    $AMCX

    CompanyDatePrice TargetRatingAnalyst
    Coeur Mining Inc.
    $CDE
    3/25/2026$27.00Outperform
    BMO Capital Markets
    Xponential Fitness Inc.
    $XPOF
    3/19/2026Strong Buy → Mkt Perform
    Raymond James
    Xponential Fitness Inc.
    $XPOF
    3/12/2026Sector Weight
    KeyBanc Capital Markets
    Xponential Fitness Inc.
    $XPOF
    2/27/2026$7.00Buy → Neutral
    Roth Capital
    Coeur Mining Inc.
    $CDE
    2/20/2026Buy → Hold
    Canaccord Genuity
    Mirum Pharmaceuticals Inc.
    $MIRM
    2/18/2026$130.00Outperform
    RBC Capital Mkts
    Louisiana-Pacific Corporation
    $LPX
    2/5/2026$15.00Outperform
    Oppenheimer
    Evotec SE
    $EVO
    2/3/2026Buy
    Berenberg
    More analyst ratings

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BMO Capital Markets resumed coverage on Coeur Mining with a new price target

    BMO Capital Markets resumed coverage of Coeur Mining with a rating of Outperform and set a new price target of $27.00

    3/25/26 8:52:52 AM ET
    $CDE
    Precious Metals
    Basic Materials

    Xponential Fitness downgraded by Raymond James

    Raymond James downgraded Xponential Fitness from Strong Buy to Mkt Perform

    3/19/26 8:25:33 AM ET
    $XPOF
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    KeyBanc Capital Markets initiated coverage on Xponential Fitness

    KeyBanc Capital Markets initiated coverage of Xponential Fitness with a rating of Sector Weight

    3/12/26 8:55:45 AM ET
    $XPOF
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Boulet Virginia bought $136,175 worth of shares (6,500 units at $20.95), increasing direct ownership by 3% to 228,342 units (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    3/9/26 7:35:06 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    Large owner Hrt Financial Lp bought $15,605 worth of Class A Shares (14,584 units at $1.07) and sold $9,121 worth of Class A Shares (8,368 units at $1.09), increasing direct ownership by 15% to 48,596 units (SEC Form 4)

    4 - La Rosa Holdings Corp. (0001879403) (Issuer)

    3/3/26 2:57:47 PM ET
    $LRHC
    Real Estate
    Finance

    Director Debbane Raymond bought $2,980 worth of shares (2,000 units at $1.49), increasing direct ownership by 0.11% to 1,906,186 units (SEC Form 4)

    4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

    2/27/26 8:33:21 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 3 filed by new insider Yang Guang George

    3/A - Bitdeer Technologies Group (0001899123) (Issuer)

    3/31/26 7:38:17 AM ET
    $BTDR
    Finance: Consumer Services
    Finance

    Amendment: SEC Form 3 filed by new insider Trainor-Degirolamo Sheldon

    3/A - Bitdeer Technologies Group (0001899123) (Issuer)

    3/31/26 7:37:54 AM ET
    $BTDR
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Jianchun Liu

    3 - Bitdeer Technologies Group (0001899123) (Issuer)

    3/31/26 7:37:29 AM ET
    $BTDR
    Finance: Consumer Services
    Finance

    $AAN
    $AGRI
    $ALLG
    $AMCX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 21, 2025 - FDA Approves First Treatment for Cerebrotendinous Xanthomatosis, a Rare Lipid Storage Disease

    For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

    2/21/25 11:48:20 AM ET
    $MIRM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

    Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

    5/30/23 10:02:49 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AAN
    $AGRI
    $ALLG
    $AMCX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Venus Concept Inc.

    SCHEDULE 13D/A - Venus Concept Inc. (0001409269) (Subject)

    4/1/26 6:14:33 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Virgin Galactic Holdings Inc.

    S-8 - Virgin Galactic Holdings, Inc (0001706946) (Filer)

    4/1/26 4:32:06 PM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form NT 10-K/A filed by La Rosa Holdings Corp.

    NT 10-K/A - La Rosa Holdings Corp. (0001879403) (Filer)

    4/1/26 4:12:23 PM ET
    $LRHC
    Real Estate
    Finance

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kanen Wealth Management Urges Xponential Fitness (NYSE: XPOF) Board to Initiate Strategic Review, Including Potential Sale

    To the Board of Directors of Xponential Fitness, Inc. (NYSE:XPOF): COCONUT CREEK, Fla., April 01, 2026 (GLOBE NEWSWIRE) -- Kanen Wealth Management, LLC, as owners of approximately 4% of the Company's outstanding Class A shares, urges the Board to immediately initiate and publicly announce a formal review of strategic alternatives, including a sale of the Company. The Board should establish an independent Special Committee and retain a qualified financial advisor to conduct a good-faith process with credible bidders. This letter follows a private communication we sent to the Board in March 2026. In our view, our conversations with the Company's former CFO and current Chairman suggest a de

    4/1/26 12:00:00 PM ET
    $XPOF
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger

    TORONTO, April 01, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global medical aesthetic technology leader, today announced the successful completion by affiliates of Madryn Asset Management, LP ("Madryn") of a short-form merger transaction, pursuant to which 100% ownership of the Company's common stock is now consolidated under funds managed by Madryn (the "Short-form Merger"). The Short-form Merger was consummated on March 30, 2026, and the Company is now privately held by Madryn. All common shares outstanding prior to the Short-form Merger (other than shares held directly or indirectly by Madryn) have been converted, subject to appraisal rights, into

    4/1/26 9:02:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Leadership Updates

    Live Leadership Updates

    View All

    Virgin Galactic Appoints Megan Prichard as Chief Growth Officer

    Veteran technology leader and former Uber executive to drive revenue growth, market expansion and customer acquisition for human spaceflight and research missions Virgin Galactic Holdings, Inc. (NYSE:SPCE) ("Virgin Galactic" or the "Company"), a leader in commercial spaceflight and advanced aerospace technology, today announced the appointment of Megan Prichard as its new Chief Growth Officer (CGO), effective April 6. In this newly established role, Prichard will lead the Company's integrated growth and revenue strategy across all business lines while strengthening Virgin Galactic's position as the premier platform for suborbital spaceflight expeditions and scientific research. Prichard

    3/23/26 4:05:00 PM ET
    $BL
    $SPCE
    Computer Software: Prepackaged Software
    Technology
    Transportation Services
    Consumer Discretionary

    Alan Walshe Appointed General Manager of Takeda Canada

    A proven people‑focused commercial strategist with extensive global experience to lead Takeda Canada's next chapter of growth and impact.TORONTO, March 2, 2026  /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Alan Walshe as General Manager for Canada. Alan brings 17 years of experience with Takeda and its predecessor companies, most recently serving as Global Head of Commercial Strategy for the Plasma‑Derived Therapies Business Unit."Alan's depth of commercial expertise and global perspective, combined with his people‑focused leadership sty

    3/2/26 7:59:00 AM ET
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

    RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) (TASE:XTLB.TA) (the "Company" or "XTL"), announced today that it has received a letter (the "Letter") from The Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a "public shell", and that continued listing of the Company's American Depositary Shares ("ADSs") is no longer warranted. The Company intends to request a hearing (the "Hearing") to appeal the delisting process before a Nasdaq Heari

    2/27/26 4:30:00 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Led to the Purchase at Aerovate Therapeutics Inc. on Jun 20?

    Recently, on June 20, 2024, a notable insider purchase was made at Aerovate Therapeutics Inc. Director Ra Capital Management, L.P. bought $1,549,944 worth of shares, acquiring 928,110 units at $1.67 per share as reported in the SEC Form 4. Insider transactions like these are closely watched by investors as they can provide valuable insights into the company's prospects. When analyzing insider transactions, it is essential to look for patterns and trends among multiple transactions to gauge the overall sentiment within the company. Several other SEC Form 4 filings were made around the same time, on June 7, 2024, by various insiders at Aerovate Therapeutics Inc. These included transactions by

    6/21/24 3:23:59 PM ET
    $AVTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Financials

    Live finance-specific insights

    View All

    Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration

    JERUSALEM, April 1, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI); ("Scinai" or the "Company"), a biopharmaceutical company operating a dual R&D and CDMO business model designed to combine therapeutic innovation with revenue-generating drug development and manufacturing services, today reported financial results for the year ended December 31, 2025. Corporate and Financial HighlightsCDMO revenues doubled year-over-year to $1.3 million, reflecting continued commercial traction and execution of development and manufacturing programsExpanded CDMO platform post year-end through the acquisition of Recipharm Israel and entry into a strategic commercial collaboration with Reciph

    4/1/26 7:35:00 AM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Workhorse Group Reports Fourth Quarter and Full Year 2025 Results

    Revenue of $9.7 million in Q4 2025, up 64% year-over-year; full year revenue of $21.2 million, up 201% year-over-yearOn a pro forma basis, combined company revenue of $34.0 million for full year 2025, compared to $13.7 million in 2024, an increase of 149%Delivered 65 vehicles in Q4 2025 and 112 vehicles for full year 2025, compared to 46 vehicles in full year 2024Combined delivered trucks surpassed 20 million real-world miles across more than 1,100 deployed vehiclesTargeting $20 million in annualized cost synergies from merger integration as the company exits 2026Announced a 140 kWh battery configuration of W56 step van in response to customer demand DETROIT, March 31, 2026 (GLOBE NEWSWIR

    3/31/26 4:05:00 PM ET
    $WKHS
    Auto Manufacturing
    Industrials

    Virgin Galactic Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Sales Open for Virgin Galactic Spaceflight Expeditions - Priced At $750K First of Two New SpaceShips Progressing to Ground Test Phase in April; Flight Test Phase Begins Q3 2026 Commercial Spaceflight Operations with First New SpaceShip Continue on Track for Q4 2026 Second New SpaceShip Expected to Enter Service Between Late Q4 2026 and Early Q1 2027 Virgin Galactic Holdings, Inc. (NYSE:SPCE) ("Virgin Galactic" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided a business update. CEO Michael Colglazier said, "We completed pivotal milestones during the first quarter of 2026, and with assembly of our

    3/30/26 4:05:00 PM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    $AAN
    $AGRI
    $ALLG
    $AMCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

    SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

    12/9/24 9:33:20 PM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care